Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Asia 2022 | Highlights from ESMO Asia 2022 in HCC

Stephen L. Chan • 5 Dec 2022
ESMO Asia 2022
Gastrointestinal Cancer Liver Cancer
HIMALAYA

Stephen L. Chan, MBBS (HK), MRCP (UK), FHKCP, FHKAM (Medicine), FRCP (Edin), FRCP (Lond), Chinese University of Hong Kong, Hong Kong, discusses highlights from ESMO Asia 2022 in the field of hepatocellular carcinoma, including key clinical trials presented at the meeting. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Stephen L. Chan

1:27
The role of monotherapy TKI’s in the treatment of patients with hepatocellular carcinoma
Stephen L. Chan • 23 Oct 2023
1:40
Methods to improve quality of life and outcomes in patients with pancreatic cancer
Stephen L. Chan • 23 Oct 2023
1:40
Prognostic factors contributing to long-term survivorship in patients with hepatobiliary cancers
Stephen L. Chan • 23 Oct 2023
2:04
Hepatitis B outcomes in KEYNOTE-966: HBV+ pts on pembrolizumab + gem/cis for advanced BTC
Stephen L. Chan • 23 Oct 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals